Inst. Holders
50 funds
ACLX
Arcellx, Inc.
—
12-mo target$112.20 (-2.5%)
Insider Selling Cluster (2 insiders)High Impact Filing (9/10)34 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ACLX right now — valuation, ownership and activity at a glance.
Inst. Value
$3.4B
Inst. Activity
0 buys / 34 sells
SEC Reports
3
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 5, 2026 earnings_calendar
ACLX Q2 2026 Earnings After Market Close — 2026-08-05
Jun 30, 2026 Inst.
STATE STREET CORP — EXIT
0 shares ($0.00)
Jun 30, 2026 Inst.
Apr 28, 2026 SEC Magnetar Financial LLC — EXIT
0 shares ($0.00)
Arcellx, Inc. (ACLX) has been involuntarily delisted from Nasdaq, with the exchange filing a Form 25-NSE to remove the c
25-NSE — Impact 9/10
Apr 28, 2026 Insider
Elghandour Rami disposed of 174,887 shares
SEE REMARKS
Apr 28, 2026 Insider
Elghandour Rami disposed of 1,068,005 shares
SEE REMARKS
Apr 28, 2026 Insider
Apr 24, 2026 SEC Elghandour Rami disposed of 55,459 shares
SEE REMARKS
Arcellx filed an amended 10-K/A to include Part III disclosures (director and executive compensation, ownership, and rel
10-K/A — Impact 2/10
Analyst ratings buy % -100.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Feb 26, 2026 | Guggenheim | DOWNGRADE | Neutral | 52% |
| Feb 24, 2026 | Truist Securities | DOWNGRADE | Hold | 55% |
| Feb 24, 2026 | Evercore ISI Group | DOWNGRADE | In-Line | 59% |
| Feb 24, 2026 | UBS | DOWNGRADE | Neutral | 55% |
| Feb 24, 2026 | Citigroup | DOWNGRADE | Neutral | 55% |
| Feb 24, 2026 | Leerink Partners | DOWNGRADE | Market Perform | 49% |
| Feb 24, 2026 | Stifel | DOWNGRADE | Hold | 54% |
| Feb 23, 2026 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
| Feb 23, 2026 | Baird | DOWNGRADE | Neutral | 54% |
| Feb 23, 2026 | Needham | DOWNGRADE | Hold | 50% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 0 | 0 | 11 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 20 | 1 | 2 | 0% | |
| Mar 1, 2026 | 2 | 6 | 16 | 0 | 0 | 33% | |
| Feb 1, 2026 | 9 | 14 | 3 | 0 | 0 | 88% | |
| Jan 1, 2026 | 9 | 14 | 3 | 0 | 0 | 88% |
Price targets
Where 10 covering analysts think ACLX trades over the next 12 months.
$112.20 -2.5% upside Hold
Current$115.07 Low$82.00 Median$115.00 High$120.00 10 analysts
$82.00$120.00
Analyst rating Hold· 3.0/5 as of Jul 18, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 0 bullish, 2 bearish, 0 mixed, 1 neutral · avg impact 6.0/10.
BEARISH25-NSE9/10
Arcellx, Inc. (ACLX) has been involuntarily delisted from Nasdaq, with the exchange filing a Form 25
Apr 28, 2026
NEUTRAL10-K/A2/10
Arcellx filed an amended 10-K/A to include Part III disclosures (director and executive compensation
Apr 24, 2026
BEARISHCLUSTER7/10
Two corporate insiders at Arcellx, Inc. (ACLX) sold shares in the past week, including CFO Michelle
Feb 28, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 5, 2026
earnings_calendar
ACLX Q2 2026 Earnings After Market Close — 2026-08-05
May 20, 2026
earnings_calendar
ACLX Q1 2026 Earnings After Market Close — 2026-05-20
May 18, 2026
earnings_calendar
ACLX Q1 2026 Earnings After Market Close — 2026-05-18
May 13, 2026
earnings_calendar
ACLX Q1 2026 Earnings After Market Close — 2026-05-13
May 6, 2026
earnings_calendar
ACLX Q1 2026 Earnings After Market Close — 2026-05-06
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.02 | $-1.11–$-0.95 | 9.8% | -0.1% | 3↑ 0↓ | $0.0B | 4 |
| Next FY | $-1.48 | $-4.47–$1.95 | 64.9% | +14.5% | 0↑ 1↓ | $0.3B | 8 |
| Next Q | $-1.06 | $-1.19–$-0.96 | -13.1% | +0.0% | 3↑ 0↓ | $0.0B | 3 |
| Current FY | $-4.22 | $-4.77–$-3.85 | -3.6% | +0.0% | — | $0.1B | 5 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.019 | — |
| 7d ago | $-1.019 | — |
| 30d ago | $-1.018 | -0.001 |
| 60d ago | $-1.018 | -0.001 |
| 90d ago | $-1.101 | +0.082 |
Institutional ownership
Which big funds own ACLX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $3.4B total value (29,716,909 shares) as of 2026-Q1. Top holders: BlackRock,, Pentwater, VANGUARD. Net buying activity: 14 institutions added/increased vs 2 reduced.
Top holders — 2026-Q1
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 3,945,238 | $453.0M | 13.4% | EXIT -100.0% |
| Pentwater Capital Management LP | 2,870,000 | $329.5M | 9.7% | EXIT -100.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,425,218 | $278.5M | 8.2% | EXIT -100.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,424,818 | $278.4M | 8.2% | EXIT -100.0% |
| FIL Ltd | 2,339,192 | $268.6M | 7.9% | EXIT -100.0% |
| HBK INVESTMENTS L P | 2,278,517 | $261.6M | 7.7% | NEW |
| STATE STREET CORP | 1,675,895 | $192.4M | 5.7% | EXIT -100.0% |
| GOLDMAN SACHS GROUP INC | 1,312,155 | $150.7M | 4.5% | EXIT -100.0% |
| GEODE CAPITAL MANAGEMENT, LLC | 1,028,666 | $118.1M | 3.5% | EXIT -100.0% |
| MORGAN STANLEY | 925,813 | $106.3M | 3.1% | EXIT -100.0% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| STATE STREET CORP | EXIT | 1,675,895 | 0 | -100.0% | $0.00 |
| Magnetar Financial LLC | EXIT | 394,931 | 0 | -100.0% | $0.00 |
| PICTON MAHONEY ASSET MANAGEMENT | EXIT | 120,000 | 0 | -100.0% | $0.00 |
| GEODE CAPITAL MANAGEMENT, LLC | EXIT | 1,028,666 | 0 | -100.0% | $0.00 |
| JPMORGAN CHASE & CO | EXIT | 593,573 | 0 | -100.0% | $0.00 |
| FMR LLC | EXIT | 119,378 | 0 | -100.0% | $0.00 |
| MORGAN STANLEY | EXIT | 925,813 | 0 | -100.0% | $0.00 |
| BANK OF AMERICA CORP /DE/ | EXIT | 452,333 | 0 | -100.0% | $0.00 |
| GOLDMAN SACHS GROUP INC | EXIT | 1,312,155 | 0 | -100.0% | $0.00 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 346,092 | 0 | -100.0% | $0.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 28, 2026 | Elghandour Rami | SEE REMARKS | U | 174,887 | — | — |
| Apr 28, 2026 | Elghandour Rami | SEE REMARKS | D | 1,068,005 | — | — |
| Apr 28, 2026 | Elghandour Rami | SEE REMARKS | D | 55,459 | — | — |
| Apr 28, 2026 | Elghandour Rami | SEE REMARKS | AWARD | 147,745 | — | — |
| Apr 28, 2026 | Elghandour Rami | SEE REMARKS | D | 147,745 | — | — |
| Apr 28, 2026 | Heery Christopher | CHIEF MEDICAL OFFICER | U | 23,749 | — | — |
| Apr 28, 2026 | Heery Christopher | CHIEF MEDICAL OFFICER | D | 10,901 | — | — |
| Apr 28, 2026 | Heery Christopher | CHIEF MEDICAL OFFICER | D | 13,021 | — | — |
| Apr 28, 2026 | Heery Christopher | CHIEF MEDICAL OFFICER | AWARD | 45,138 | — | — |
| Apr 28, 2026 | Heery Christopher | CHIEF MEDICAL OFFICER | D | 45,138 | — | — |
All ACLX filing & press-release reports (3)
- 25-NSE reportApr 28, 2026
- 10-K/A reportApr 24, 2026
- CLUSTER reportFeb 28, 2026